Towards standardization of absolute SPECT/CT quantification: a multi-center and multi-vendor phantom study

Steffie M. B. Peters1,†, Niels R. van der Werf2,3,†, Marcel Segbers2, Floris H. P. van Velden4, Roel Wierts5, Koos (J.) A. K. Blokland4, Mark W. Konijnenberg2, Sergiy V. Lazarenko6, Eric P. Visser1 and Martin Gotthardt1

Abstract: Absolute quantification of radiotracer distribution using SPECT/CT imaging is of great importance for dosimetry aimed at personalized radionuclide precision treatment. However, its accuracy depends on many factors. Using phantom measurements, this multi-vendor and multi-center study evaluates the quantitative accuracy and inter-system variability of various SPECT/CT systems as well as the effect of patient size, processing software and reconstruction algorithms on recovery coefficients (RC).

Methods: Five SPECT/CT systems were included: Discovery™ NM/CT 670 Pro (GE Healthcare), Precedence™ 6 (Philips Healthcare), Symbia Intevo™, and Symbia™ T16 (twice) (Siemens Healthineers). Three phantoms were used based on the NEMA IEC body phantom without lung insert simulating body mass indexes (BMI) of 25, 28, and 47 kg/m². Six spheres (0.5–26.5 mL) and background were filled with 0.1 and 0.01 MBq/mL 99mTc-pertechnetate, respectively. Volumes of interest (VOI) of spheres were obtained by a region growing technique using a 50% threshold of the maximum voxel value corrected for background activity. RC, defined as imaged activity concentration divided by actual activity concentration, were determined for maximum (RC_max) and mean voxel value (RC_mean) in the VOI for each sphere diameter. Inter-system variability was expressed as median absolute deviation (MAD) of RC. Acquisition settings were standardized. Images were reconstructed using vendor-specific 3D iterative reconstruction algorithms with institute-specific settings used in clinical practice and processed using a standardized, in-house developed processing tool based on the SimpleITK framework. Additionally, all data were reconstructed with a vendor-neutral reconstruction algorithm (Hybrid Recon™; Hermes Medical Solutions).

Results: RC decreased with decreasing sphere diameter for each system. Inter-system variability (MAD) was 16 and 17% for RC_mean and RC_max, respectively. High BMI hampers quantification of small lesions (< 10 ml).

Conclusion: Absolute SPECT quantification in a multi-center and multi-vendor setting is feasible, especially when reconstruction protocols are standardized, paving the way for a standard for absolute quantitative SPECT.

Keywords: SPECT/CT, absolute quantification, recovery coefficient, performance evaluation

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Introduction

Accurate absolute quantification of radiotracer distribution is essential for dosimetry aimed at personalized radionuclide therapy and may improve prediction of therapy response, prevention of toxicity effects, and treatment follow-up [1, 2]. Both positron emission tomography (PET) and single-photon emission computed tomography (SPECT) hold the promise for absolute radioactivity quantification. However, for SPECT, quantification is considered less straightforward [3, 4] since its accuracy depends on a variety of factors, including the necessary use of a collimator, the varying detector trajectory, and the need for more complicated scatter correction and attenuation correction than in PET [4]. Furthermore, quantification is influenced by both the reconstruction algorithm and settings. Recent developments in corrections for photon attenuation and scatter, collimator modeling and 3D reconstruction, e.g., by including resolution recovery and noise regulation, have improved reconstruction techniques, thereby enabling absolute SPECT quantification [5]. The addition of an integrated computed tomography (CT) system not only provides an anatomical reference but enables accurate attenuation and scatter correction as well, improving quantification [6]. Nowadays, combined SPECT/CT systems have become standard clinical practice.

Standardization of protocols in such a way that quantitative results can be reliably compared between systems requires more insight in their quantitative accuracy and performance. For PET/CT, differences in absolute quantification of various systems have been extensively characterized through the European Association of Nuclear Medicine initiative of EANM Research Ltd. (EARL). As part of this initiative, quantification of the most widely used PET radiotracer, $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG), has been standardized in a multi-center setting through an accreditation program [7, 8].

Until date, no similar efforts for SPECT/CT have been carried out, which hampers multi-center research trials involving absolute SPECT quantification, especially those aimed towards dosimetry. The requirements on quantification for dosimetry are described in MIRD Pamphlet No. 23 [9]. With the advent of, for example, $^{177}$Lu-PSMA therapy [10–13], it is expected that dosimetry will play a pivotal role for reliable determination of dose response relationships. But also our understanding of biomarker studies and already well-established radionuclide therapies in thyroid cancer [14, 15] or neuroendocrine tumors [16–20] may profit from optimized quantitative SPECT imaging for sophisticated dosimetry. In addition, quantitative measurements are increasingly used in diagnosis or disease monitoring [21]. Several studies investigated the quantitative performance of SPECT for a variety of radionuclides, including technetium-$^{99}$m ($^{99m}$Tc) [22, 23], indium-$^{111}$ (In$^{111}$In) [24–26], iodine-$^{131}$ (I$^{131}$) [27], lutetium-$^{177}$ ($^{177}$Lu) [28], yttrium-$^{90}$ (Y$^{90}$) [29], or a combination of these [30, 31]. However, comparing these results of absolute quantification may be difficult as they were obtained on different SPECT/CT systems. Seret et al. [32] compared four SPECT/CT systems for their quantitative capabilities and found that for objects which dimensions exceeded the SPECT spatial resolution several times, quantification was possible within a 10% error. For smaller structures, larger errors were observed necessitating partial volume effect correction. Furthermore, reconstruction artifacts degraded the accuracy of quantification. Hughes and colleagues compared image quality [33] of three SPECT/CT systems for cardiac applications. They showed that these systems performed differently in terms of quantitative accuracy, contrast, signal-to-noise, and
uniformity. In a different study [34] in which they compared the same three SPECT/CT systems, they showed that image resolution is very much dependent on the reconstruction algorithm. In recent years, various SPECT/CT and software vendors have responded to the increasing need for SPECT quantification and now commercially offer software packages for quantification of several radionuclides including $^{99m}$Tc, $^{111}$In, $^{131}$I, and $^{177}$Lu [35–38].

The aim of this study is to compare absolute quantification for state-of-the-art SPECT/CT systems from different vendors at different imaging centers for $^{99m}$Tc. Multiple quantitative reconstruction algorithms that are currently commercially available are included in the comparison. The quantitative accuracy and inter-system variability of recovery coefficients (RC) are determined using various phantom experiments. The effects of lesion volume, patient size, reconstruction algorithm, and post-processing on RC are investigated. The results of these comparisons provide a first step towards a vendor-independent standard for absolute quantitative SPECT/CT that would allow transferability of the obtained metrics [39].

### Methods

#### SPECT/CT systems

Data were acquired on five state-of-the-art SPECT/CT systems from three manufacturers: a Discovery NM/CT 670 Pro (GE Healthcare, Milwaukee, USA), a Precedence 6 (Philips Healthcare, Best, The Netherlands), a Symbia Intevo 6, and two Symbia T16’s (Siemens Healthineers, Erlangen, Germany) (Table 1).

#### Phantoms

A NEMA IEC body phantom without lung insert was used (Fig. 1). This phantom represents a patient with a body mass index (BMI) of 25 kg/m² (which is considered

### Table 1  Characteristics of all used SPECT/CT systems with LEHR collimator

| System | Discovery NM/CT 670 Pro | Precedence 6 | Symbia Intevo 6 | Symbia T16 |
|--------|-------------------------|--------------|-----------------|-----------|
| Detector crystal | 3/8” NaI | 3/8” NaI | 3/8” NaI | 3/8” NaI |
| PMT* | 59 | 55 | 59 | 59 |
| FOV* | 40 x 54 cm | 38.1 x 50.8 cm | 38.7 x 53.3 cm | 38.7 x 53.3 cm |
| Hole shape | Hexagonal | Hexagonal | Hexagonal | Hexagonal |
| Number of holes (x 1000) | Not specified | 86.4 | 148 | 148 |
| Collimator hole diameter | 1.50 mm | 1.40 mm | 1.11 mm | 1.11 mm |
| Hole length | 35 mm | 32.8 mm | 24.05 mm | 24.05 mm |
| Septal thickness | 0.2 mm | 0.152 mm | 0.16 mm | 0.16 mm |
| Sensitivity for $^{99m}$Tc @ 10 cm | 72 cps/MBq | 66 cps/MBq | 91 cps/MBq | 91 cps/MBq |
| Septal penetration @ 140 keV | 0.3% | 1.3% | 1.5% | 1.5% |
| Planar resolution† | 7.4 mm | 7.4 mm | 7.5 mm | 7.5 mm |
| SPECT central resolution† | 6.4 mm | 4.4 mm | 4.4 mm | 4.4 mm |
| SPECT peripheral radial resolution† | 5.7 mm | 4.2 mm | 4.0 mm | 4.0 mm |
| SPECT peripheral tangential resolution† | 5.1 mm | 4.3 mm | 3.9 mm | 3.9 mm |

* (CFOV (center) field of view, PMT photomultiplier tube
† Spatial resolution without scatter (LEHR collimator at 10 cm, (full width at half maximum (FWHM) in CFOV [mm], 3/8” crystal)
normal) and contains six spheres with inner diameters (and corresponding volumes) of 10 mm (0.5 ml), 13 mm (1.2 ml), 17 mm (2.6 ml), 22 mm (5.6 ml), 28 mm (11.5 ml), and 37 mm (26.5 ml). To evaluate the effect of patient size on SPECT quantification, two additional custom-made phantoms were used on some systems that were similar to the shape of the NEMA IEC body phantom, but with larger diameters, reflecting a larger BMI of obese patients (Table 2). The spheres from the NEMA IEC body phantom were also used for the increased body size phantoms.

For all phantoms, the spheres and background compartment were filled with a homogeneous solution of $^{99m}$Tc-pertechnetate in water with a concentration of approximately 100 kBq/ml and 10 kBq/ml, respectively, resulting in a sphere-to-background ratio of 10:1 similar to EARP guidelines for $^{18}$F-FDG PET imaging [8]. All $^{99m}$Tc-pertechnetate activities were measured in the clinical radionuclide dose calibrators present in the participating hospitals, which undergo regular quality control according to national guidelines [40].

Fig. 1 The phantoms used to determine the RC. Upper phantom: NEMA IEC body phantom. Lower two phantoms: custom-made phantoms reflecting a larger body mass index (BMI, kg/m$^2$) of patients. Note that the lower two phantoms are depicted without spheres inset.
Data acquisition and reconstruction

Harmonized acquisition protocols were used for all measurements. Images were acquired with a low-energy high-resolution (LEHR) collimator (Table 1) in step and shoot mode, 128 projections (64 per detector head) (Discovery NM/CT 670 Pro: 120 projections, 60 per detector head), 20 s per projection, zoom factor 1.0, matrix size 128 × 128 (Symbia Intevo, 256 × 256), a photon energy window of 140 keV ± 15% and the detector trajectory set to body contour. Data from the standard NEMA phantom were acquired five times repetitively to assess system-specific repeatability. The time per angle was adjusted to obtain similar count statistics for each replicate.

Data were reconstructed with two reconstruction methods to assess its influence on quantification. First, vendor-specific 3D iterative reconstruction algorithms that included scatter correction, CT-based attenuation correction (for acquisition parameters see Additional file 1: Table S1) and resolution recovery with institute-specific settings used in clinical practice [3] were used. This included two quantitative reconstruction algorithms that are currently commercially available (GE Q.Metrix and Siemens xSPECT Quant). Second, data were reconstructed with a vendor-neutral quantitative reconstruction algorithm (Hybrid Recon v1.1.2; Hermes Medical Solutions, Stockholm, Sweden) (Table 3).

Calibration factor

SPECT/CT systems were cross-calibrated for $^{99m}$Tc with the corresponding dose calibrators according to the manufacturer’s recommendation or to the center’s standard practice (Additional file 1: Table S2). Either one large or multiple smaller cylindrical regions of interest (ROIs) where drawn to obtain a calibration factor (CF) according to:

$$CF \left[ \frac{\text{cps/ml}}{\text{kBq/ml}} \right] = \frac{\left( \frac{\mu}{t \cdot n \cdot \nu} \right)}{A} \quad (1)$$

where $\mu$ is the mean voxel value in the reconstructed image, $t$ is the time per projection, $n$ is the number of projections, $\nu$ is the voxel size, and $A$ is the actual activity concentration in the phantom.

Analysis

To evaluate the absolute quantification of different SPECT/CT systems, RC for background and all six spheres were determined. RC was defined as the ratio of the measured activity concentration ($a$) and the true activity concentration ($A$) for each sphere:
Volumes of interest (VOIs) for each sphere were determined with a region growing algorithm for which the cut-off threshold was calculated by [41]:

\[
VV_{\text{thresh}} = 0.5 \cdot (VV_{\text{max,sphere}} + VV_{\text{mean,bg}})
\]  

(3)

where \(VV_{\text{thresh}}\) is the threshold voxel value, \(VV_{\text{max,sphere}}\) is the maximum voxel value in the sphere VOI, and \(VV_{\text{mean,bg}}\) is the mean voxel value in the background VOI. \(VV_{\text{mean,bg}}\) was determined by placing six cylindrical VOIs (diameter 4–5 cm) in a uniform region within the phantom.

The maximum and mean activity concentration for each sphere were determined, which resulted in both maximum and mean RC values, denoted as \(RC_{\text{max}}\) and \(RC_{\text{mean}}\), respectively.

\[
RC = \frac{a}{A}
\]  

(2)

Table 3: Reconstruction and quantification parameters and processing software used in this study

| System          | Imaging center                     | Reconstruction          | Quantification       | Post-reconstruction filter | Processing          | Attenuation correction | Scatter Correction | Image voxel size               |
|-----------------|------------------------------------|-------------------------|----------------------|---------------------------|----------------------|------------------------|----------------------|-------------------------------|
|                 | Leiden University Medical Center    | OSEM* + Evolutions with PSF* correction | QMetrix Manual analysis | None                        | GE Xeleris 4.0 workstation | CT-based, bilinear conversion of HU into attenuation coefficients at 140 keV | DEW* (120 keV ± 10%) | 2.21 × 2.21 mm³ × 2.21 mm³      |
|                 | Maastricht University Medical Center | OSEM* + Astonish with PSF* correction | Manual analysis      | None                        | Philips Extended Brilliance Workspace | CT-based, HU segmentation using a step-like law, bilinear conversion of HU into attenuation coefficients at 140 keV | Kernel based DEW* | 4.7 × 4.7 mm³ × 4.7 mm³        |
|                 | Noord West ziekenhuis Grop         | Weighted Conjugate Gradient + xSPECT with PSF* correction | QMetrix Manual analysis | Siemens Syngo.via           | Siemens Inveon Research Workplace | CT-based, bilinear conversion of HU into attenuation coefficients at 140 keV | DEW* (119 keV ± 7.5%) | 2.54 × 2.54 mm³ × 2.54 mm³      |
|                 | Radboud University Medical Center  | OSEM* + Flash 3D with PSF* correction | Hermes SUV SPECT     | Siemens Syngo.via           | Hermes Hybrid Viewer Workplace | CT-based, bilinear conversion of HU into attenuation coefficients at 140 keV | Monte Carlo-based DEW* | 4.8 × 4.8 mm³ × 4.8 mm³        |
|                 | Erasmus University Medical Center  | OSEM* + Hybrid Recon V1.2 with PSF* correction | Hermes SUV SPECT     | Siemens Syngo.via           | Hermes Hybrid Viewer Workplace | CT-based, bilinear conversion of HU into attenuation coefficients at 140 keV | Monte Carlo-based DEW* | 4.8 × 4.8 mm³ × 4.8 mm³        |

* OSEM ordered subset expectation maximization, PSF point spread function, DEW dual energy window
† Initial acquisition was performed with 128 × 128 matrix size and corresponding voxel size of 4.42 × 4.42 × 4.42 mm³. For quantification purposes this was interpolated to a 256 × 256 matrix size and corresponding voxel size of 2.21 × 2.21 × 2.21 mm³, as recommended by the vendor.
The repeatability of the RC for each system was assessed with the reconstructed data of the five repetitive measurements by calculating the median absolute deviation (MAD) for each sphere diameter according to:

$$\text{MAD} = \text{median}(|\text{RC}_i - \overline{\text{RC}}|)$$

where \(\text{RC}_i\) is the recovery coefficient of measurement \(i\) and \(\overline{\text{RC}}\) is the median recovery coefficient of all repetitive measurements.

The MAD was also used to assess variability between systems for each sphere diameter. For each sphere, the median RC from each system was used in Eq. 4. This resulted in a sphere-specific MAD.

In addition to center-specific image analysis, all images were processed automatically in a standardized way using in-house developed software in Python which uses the SimpleITK toolkit region growing algorithm to determine sphere-specific VOIs using the same region growing algorithm as described above (Table 4) [42, 43].

**Results**

**Calibration factor**

The calibration factors that were used to determine the RC for each system can be found in Table 4.

**Recovery coefficient**

Differences (indicated as mean ± standard deviation) between the RC determined using standardized processing software versus center-specific processing software were 2 ± 3% for \(\text{RC}_{\text{mean}}\) and 0 ± 3% \(\text{RC}_{\text{max}}\). Since these differences were considered negligible, all data were processed using the standardized processing software (Python) as described earlier (performed centralized by two authors on all data).

The median recovery coefficient of the background compartment of the phantom was 1.01 (range, 0.93–1.07). The sphere-to-background activity concentration ratio was 10.6 ± 0.4:1 for all systems. Images obtained on all five systems showed different visual results (Fig. 2).

For all systems, both \(\text{RC}_{\text{mean}}\) and \(\text{RC}_{\text{max}}\) decreased with decreasing sphere diameter (Fig. 3a–e). RC for the smallest sphere diameter (10 mm) could not be obtained because of the low contrast between the smallest sphere and the background for the used activity concentration ratio. Therefore, this sphere diameter is not considered in the remainder of this study. The variability in RC between systems is visualized in Fig. 3f.

**Table 4** Calibration factors for center-specific and vendor-neutral reconstructions, calculated for 128 projections and 20 s/projection

| System                  | Center-specific CF* (cps/kBq) | CF for Hermes SUV SPECT (kBq/cts) |
|-------------------------|-------------------------------|----------------------------------|
| Discovery NM/CT 670 Pro | 0.075                         | 0.128                            |
| Precedence 6            | 0.0986                        | 0.143                            |
| Symbia Intevo 6         | 1.00 [-]†                     | 0.112                            |
| Symbia T16 system 1     | 0.0951                        | 0.114                            |
| Symbia T16 system 2     | 0.110                         | 0.110                            |

* CF calibration factor  
† Data is already quantitative in kBq therefore no calibration factor is stated
For each system, RC repeatability, expressed as the MAD, was best for the largest spheres, but good repeatability was shown for all sphere diameters (Table 5).

**Effect of reconstruction algorithm on RC**

Vendor-neutral reconstruction showed a large decrease in inter-system variability (Figs. 4 and 5). This finding is further confirmed by the MAD for reconstruction with vendor-specific versus vendor-neutral software (Table 6), which shows a median MAD of 0.10 and 0.17 (16 and 17%) for the RC\(_\text{mean}\) and RC\(_\text{max}\) of vendor-specific reconstruction, and a decreased median MAD of 0.04 and 0.05 (4 and 5%) for the RC\(_\text{mean}\) and RC\(_\text{max}\) of vendor-neutral reconstruction, respectively.

---

**Fig. 2** Images of the NEMA IEC body phantom for all systems, reconstructed with a vendor-specific algorithm.

**Fig. 3** Recovery coefficient as a function of sphere diameter for all systems separately (a–e) and for all systems combined (f), for data reconstructed with a vendor-specific algorithm. Median and box plot for five repetitive measurements per system. (a) GE Discovery NM/CT 670 Pro, (b) Philips Precedence 6, (c) Siemens Symbia Intevo 6, (d) Siemens Symbia T16 system 1, (e) Siemens Symbia T16 system 2, (f) Median RC values for all systems combined.
Effect of patient size on RC

Medium and large phantom data were only reconstructed using a vendor-neutral algorithm, since results for the small phantom showed the smallest variability between systems for these settings. It can be seen in Fig. 6 that variability of RC between systems increased in larger phantom volumes. Furthermore, smaller sphere diameters showed lower quantitative accuracy (lower RC values) indicating that reliable quantification of small volumes (< 10 ml) in larger (patient) volumes is more challenging.

Discussion

This study is a considerable step towards standardization of absolute SPECT quantification by investigating the quantitative accuracy of different SPECT/CT systems. The quantitative accuracy of individual SPECT-CT systems was assessed earlier for the GE Discovery NM/CT 670 system [5], the Siemens Symbia Intevo system [44] and the Hermes SUV SPECT quantitative reconstruction algorithm [36]. Although an earlier study by Seret et al. [32] also compared the quantitative capabilities of four SPECT/CT cameras, our study included the current state-of-the-art quantitative SPECT/CT systems that enable absolute quantification that were not available at that time.

Many factors contribute to the uncertainty in quantification even if acquisition protocols are standardized, including VOI outlining methodology, operator variability and activity measurement (dose calibrator uncertainty, cross calibration between dose

| Table 5 | MAD per system (median and range over all sphere diameters) for data reconstructed using a vendor and center-specific algorithm |
|---------|------------------------------------------------------------------------------------------------------------|
|         | RC_{mean} | RC_{max} |
| Discovery NM/CT 670 Pro | 0.02 (0.01—0.08) | 0.06 (0.02—0.10) |
| Precendence 6 | 0.02 (0.00—0.04) | 0.03 (0.00—0.06) |
| Symbia Intevo 6 | 0.01 (0.01—0.03) | 0.01 (0.00—0.05) |
| Symbia T16 (1) | 0.02 (0.00—0.04) | 0.02 (0.01—0.05) |
| Symbia T16 (2) | 0.07 (0.00—0.09) | 0.09 (0.03—0.19) |

Fig. 4 Images of the NEMA IEC body phantom for all systems, reconstructed with a vendor-neutral algorithm.
calibrator, and SPECT/CT system) [45] and in our study also phantom preparation. The median RC in the background compartment was found to be 1.01, which indicated reliable acquisition, reconstruction and analysis. However, for some systems and measurements, the background RC was as low as 0.93 or as high as 1.07. This deviation might of course also influence the sphere RC values and thereby introduce an increase in variability between quantification on different systems. Furthermore, this study showed that the largest contribution for inter-system variation is due to vendor-specific reconstruction settings. Vendor-neutral reconstruction reduced this variation two to threefold (median MAD). It is therefore paramount to harmonize SPECT/CT image reconstructions in a multi-center/multi-vendor setting.

In a clinical setting, it is expected that the variability in quantification between SPECT/CT systems will increase, due to for example patient positioning and patient volume (BMI). To this end, we compared the recovery of the hot spheres in differently sized phantoms on several SPECT/CT systems. Only minor, not clinically relevant differences between the phantoms representing a BMI of 25 and 28 kg/m² were found, while this change in BMI implies a rather significant increase in patient circumference. We therefore expect that for patients with a normal to slightly increased BMI, it is not necessary to take patient circumference into account for quantification. For a high BMI of 47 kg/m² on the other hand, activity could not be recovered for the smaller sphere diameters. This might be explained by the increased attenuation, decreased signal-to-noise ratio, and decreased spatial resolution due to increased source-detector distance in these larger volumes. This means that in patients with a high BMI, quantifying smaller lesions will be more challenging. Using more iterations in the reconstruction of images of larger patients might improve convergence and thereby improve resolution.

Table 6 MAD per sphere diameter for all systems combined, using either vendor-specific or vendor-neutral reconstruction algorithms.

| Sphere diameter | \( R_{\text{mean}} \) Vendor-specific | \( R_{\text{mean}} \) Vendor-neutral | \( R_{\text{max}} \) Vendor-specific | \( R_{\text{max}} \) Vendor-neutral |
|-----------------|--------------------------------------|------------------------------------|--------------------------------------|------------------------------------|
| 37 mm           | 0.01                                 | 0.05                               | 0.03                                 | 0.05                               |
| 28 mm           | 0.10                                 | 0.02                               | 0.16                                 | 0.04                               |
| 22 mm           | 0.20                                 | 0.04                               | 0.28                                 | 0.06                               |
| 17 mm           | 0.11                                 | 0.04                               | 0.18                                 | 0.11                               |
| 13 mm           | 0.09                                 | 0.04                               | 0.13                                 | 0.04                               |

Fig. 5 Recovery coefficient for all systems combined as a function of sphere diameter for vendor-specific reconstruction (a) and vendor-neutral reconstruction (b).
and prevent artifacts, which was also shown for SPECT/CT myocardial perfusion studies by Celler et al. [46]. The effect of increased attenuation could be canceled by an increase in scan time per projection or by increasing patient dose. The impact of scan time and dosage on image quality and image quantification is interesting to investigate further, but this was not within our scope.

The phantom used in this study did not contain lung, air, or bone components. Therefore the results mainly reflect quantification accuracy for soft tissue lesions. Experiments were performed using $^{99m}$Tc-pertechnetate. This radionuclide is the most widely used in SPECT imaging, and quantification of $^{99m}$Tc holds potential in for example myocardial perfusion imaging [47], functional lung scanning [48], selective internal radiation therapy (SIRT) of liver tumors [49, 50], quantification in bone lesions [51, 52], and therapy monitoring in locally advanced breast cancer [5]. In addition, since the radiotracer is widely available, it served as a suitable radionuclide to compare absolute quantification performance of SPECT/CT systems.

In the current study, an activity concentration ratio of 1:10 was used between the background and spheres, based on the ratio used for the same phantom in the EARL accreditation program. With lower activity concentration ratios, lower RC values are expected due to partial volume effects.

For one system, matrix size changes were necessary between vendor-specific and vendor-independent reconstructions. With this change, it is uncertain whether the improved inter-scan variability is due to the vendor-neutral reconstruction algorithm, or to the change in matrix size. It was, however, the aim of our study to assess whether vendor-neutral reconstruction would improve inter-scan variability. Which underlying parameter caused this improvement was not the goal of our study.

Both vendor dependent as well as vendor-neutral reconstructions showed Gibbs artifacts for all systems, which is a known result of resolution modeling. These artifacts occur especially in phantom reconstructions, with high contrast changes between different structures. In our study, a large contrast change was present between the inside and outside of the spheres. Despite this large contrast change, and its accompanying Gibbs artifact, all systems showed $R_{\text{mean}}$ values approaching unity for larger

![Fig. 6](image-url)
sphere sizes. When sphere size decreases, the edge ring artifacts will come very close to each other and eventually merge, resulting in a too high activity in the center of the sphere.

In this study, only one vendor-neutral reconstruction algorithm was used. In theory, another reconstruction algorithm, although not commercially available at this moment, could potentially influence the resulting metrics. For the current study, however, our aim was to assess the influence of the reconstruction algorithm on RC measurements which could be assessed by using a vendor-neutral algorithm.

Knowledge gained from this study can be used to assess the absolute quantitative accuracy for other radionuclides as well. This can serve as input for a standardization program for absolute SPECT quantification which can be used to improve sophisticated clinical dosimetry in radionuclide therapy studies, especially in a multi-center setting.

**Conclusion**

This study shows that absolute SPECT quantification is feasible in a multi-center and multi-vendor setting. With center-specific reconstructions, variability between systems was 0.01–0.20 and 0.03–0.28 (MAD) for RC\textsubscript{mean} and RC\textsubscript{max}, respectively. Standardized reconstruction decreases this variability to 0.02–0.05 and 0.04–0.11. Variation between centers is mainly caused by the use of different reconstruction algorithms and/or settings. Patient size showed to be relevant for quantification, as it was observed that high patient volume (BMI 47 kg/m\textsuperscript{2}) resulted in an increased variability among systems and impeded quantification of small lesions (< 10 ml). Close agreement between vendors and centers is key for reliable multi-center dosimetry and quantitative biomarker studies. This study serves as a first step towards a vendor-independent standard for absolute quantification in SPECT/CT.

**Supplementary information**

Additional file 1: Table S1. Settings of low dose CT protocols used for attenuation correction. Table S2. Cross-calibration protocols for dose calibrators to SPECT/CT system according to vendor recommendations.

**Abbreviations**

\textsuperscript{111}In: Indium-111; \textsuperscript{131}I: Iodine-131; \textsuperscript{177}Lu: Lutetium-177; \textsuperscript{90}Yt: Yttrium-90, \textsuperscript{99m}Tc: Technetium-99m; BMI: Body mass index; CF: Calibration factor; CT: Computed tomography; DEW: Dual energy window; EARL: EANM Research Ltd.; FDG: Fluorodeoxyglucose; LEHR: Low-energy high-resolution; MAD: Median absolute deviation; OSEM: Ordered subset expectation maximization; PET: Positron emission tomography; PSF: Point spread function; RC: Recovery coefficient; RC\textsubscript{max}: Max recovery coefficient; RC\textsubscript{mean}: Mean recovery coefficient; ROI: Region of interest; SIRT: Selective internal radiation therapy; SPECT: Single-photon emission computed tomography; TEW: Triple energy window; VOI: Volume of interest

**Acknowledgements**

The authors would like to thank Evert-Jan Woudstra and Antoi Meeuwis for their contribution in acquiring data.

**Author’s contributions**

All authors were involved in the experimental design and analysis and interpretation of the data. SMBP performed measurements for Radboud University Medical Center and took the lead in writing this manuscript. NRvdW, MS and MK performed measurements for Erasmus Medical Center. Additionally, NRvdW took the lead in analyzing the data and MS was responsible for writing the Python code. FHPvV and JAKB performed measurements for Leiden University Medical Center. SVL performed measurements for Noordwest Ziekenhuisgroep. EV and MG took the (initial) lead in the design of this study. All authors were involved in writing and reviewing the manuscript, and they all read and approved the final manuscript.

**Funding**

The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 602812 (BetaCure).
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Radiology and Nuclear Medicine, Radboudumc, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
2 Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
3 Department of Medical Physics, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
4 Department of Radiology, Section of Medical Physics, Leiden University Medical Center, Leiden, The Netherlands.
5 Department of Radiology and Nuclear Medicine, Maastricht UMC+, Maastricht, The Netherlands.
6 Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands.

Received: 26 August 2019 Accepted: 5 December 2019

Published online: 26 December 2019

References

1. Zanzonico PB, Bigler RE, Sguerou G, Strauss A. Quantitative SPECT in radiation dosimetry. Seminars in nuclear medicine. Elsevier; 1989.
2. Potrebko PS, Shridhar R, Biagioli MC, Sensakovic WF, Andl G, Poleszczuk J, et al. SPECT/CT image-based dosimetry for Yttrium-90 radionuclide therapy: application to treatment response. Journal of Applied Clinical Medical Physics. 2018; 19(5):435–43.
3. Bailey DL, Willsonon KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013;54(1):83–9.
4. Bailey DL, Willsonon KP. Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality. European journal of nuclear medicine and molecular imaging. 2014;44(1):17–25.
5. Collarino A, Pereira Arias-Bouda LM, Valdés Olmos RA, van der Tol P, Dibbets-Schneider P, de Geus-Oei LF, et al. Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer. Medical physics. 2018;45(5):2143–53.
6. Vandervoorst E, Celler A, Harrop R. Implementation of an iterative scatter correction, the influence of attenuation map quality and their effect on absolute quantitation in SPECT. Physics in Medicine & Biology. 2007;52(5):1527.
7. Boellaard R, O’Doherty MJ, Weber WA, Motaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European journal of nuclear medicine and molecular imaging. 2010;37(1):1181.
8. Boellaard R, Delgado-Bolton R, Owen WJ, Giuammarie F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. European journal of nuclear medicine and molecular imaging. 2015; 42(2):328–54.
9. Dewaraja YK, Frey EC, Sguerou G, Brill AB, Roberson P, Zanzonico PB, et al. MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. Journal of Nuclear Medicine. 2012;53(8):1310–25.
10. Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with 177 Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI research. 2015;5(1):36.
11. Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177 Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. European journal of nuclear medicine and molecular imaging. 2016;46(1):42–51.
12. Kabasakal L, Abugheith M, Aygün A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of 177 Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. European journal of nuclear medicine and molecular imaging. 2015;42(1):1976–83.
13. Kratochwil C, Gesiel FL, Stefanova M, Benesova M, Bronzel M, Aftah-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016;57(8):1170–6.
14. Lustig M, Clarke S, Dietlein M, Lassmann M, Lind P, Owen W, et al. Guidelines for radionuclide therapy of differentiated thyroid cancer. European journal of nuclear medicine and molecular imaging. 2008;35(10):1941.
15. Sguerou G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. Journal of Nuclear Medicine. 2004;45(8):1366–72.
16. Boden L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90 Y-DOTATOC and 177 Lu-DOTATATE: the role of associated risk factors. European journal of nuclear medicine and molecular imaging. 2008;35(10):1847–56.
17. Cives M, Strosberg J. Radionuclide therapy for neuroendocrine tumors. Current oncology reports. 2017;19(2):9.
18. Strosberg JR, Wolfen EM, Chazen B, Kuhle MH, Bushnell DL, Caplin ME, et al. NETTER-1 phase III: progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. American Society of Clinical Oncology; 2016.
